Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm

被引:0
|
作者
Ren-Wen Ho
Po-Chiung Fang
Tsai-Ling Chao
Chun-Chih Chien
Ming-Tse Kuo
机构
[1] Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine,Department of Ophthalmology
[2] College of Medicine,Graduate Institute of Clinical Medicine
[3] Kaohsiung Medical University,Department of Laboratory Medicine
[4] Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this study was to investigate changes in the tear film lipid layer thickness (LLT) and aqueous tear production after botulinum neurotoxin A (BoNT) injection in patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS). Eleven and six patients with BEB and HFS, respectively, who received BoNT injection were consecutively enrolled in this prospective study. The blepharospasm disability index (BSDI), blink pattern, dry eye symptoms, Schirmer test 1 findings, LLT, eyelid performance, and corneal integrity were evaluated before and after treatment. Both BEB and HSF patients experienced remarkable relief from spasms and ocular discomfort after BoNT injection. LLT, the partial blink rate, the snap-back time, the lid distraction distance, and lateral canthal laxity were significantly increased at 1 month after treatment. There were no significant changes in Schirmer test 1 findings and meibomian gland dropout. Our findings suggest that LLT, a decisive factor for tear film stability, significantly increases at 1 month after BoNT injection for BEB and HFS. A decrease in BSDI and an increase in the snap-back time may contribute to the increase in LLT; this mechanism is probably responsible for the relief from dryness after BoNT injection in patients with facial movement disorders.
引用
收藏
相关论文
共 50 条
  • [31] Successful treatment in primary blepharospasm and hemifacial spasm by botulinum toxin A
    Aiba, S.
    Tatsumoto, M.
    Hirata, K.
    MOVEMENT DISORDERS, 2010, 25 (07) : S228 - S228
  • [32] Botulinum toxin (BOTOX®) efficacy, safety in blepharospasm and hemifacial spasm
    Cabalar, M.
    Yayla, V.
    Yazar, T.
    Culha, A.
    Selcuk, O.
    Guzel, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 378 - 378
  • [33] Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin
    Winterhoff, J.
    Laskawi, R.
    HNO, 2012, 60 (06) : 479 - 483
  • [34] Therapeutic Approach to Botulinum Injections for Hemifacial Spasm, Synkinesis and Blepharospasm
    Yahalom, Gilad
    Janah, Amir
    Rajz, Gustavo
    Eichel, Roni
    TOXINS, 2022, 14 (05)
  • [35] Structural and connectivity changes after botulinum neurotoxin therapy in blepharospasmus and hemifacial spasm
    Chirumamilla, C. V.
    Deuschl, G.
    Zeuner, K. E.
    Muthuraman, M.
    Groppa, S.
    MOVEMENT DISORDERS, 2016, 31 : S554 - S554
  • [36] Is botulinum toxin Dysport effective in Botox-resistant patients with blepharospasm or hemifacial spasm?
    Badarny, S
    Susel, Z
    Zivziner, S
    Honigman, S
    MOVEMENT DISORDERS, 2002, 17 : S292 - S292
  • [37] A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm
    Lai, Kenneth K. A. Hei
    Tsang, Alan
    Kuk, Andrew K. T.
    Ko, Callie K. L.
    Chan, Edwin
    Ko, Simon T. C.
    NEURO-OPHTHALMOLOGY, 2021, 45 (05) : 293 - 300
  • [38] Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin
    Girard, B.
    Sauveur, G. de Saint
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (10): : 1553 - 1559
  • [39] Botulinum neurotoxin in the treatment of hemifacial spasm associated with myasthenia gravis
    Elavarasi, Arunmozhimaran
    Goyal, Vinay
    TOXICON, 2021, 190 : 1 - 2
  • [40] Botulinum toxin treatment of hemifacial spasm and blepharospasm: Objective response evaluation
    Thussu, A
    Barman, CR
    Prabhakar, S
    NEUROLOGY INDIA, 1999, 47 (03) : 206 - 209